Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cystic Fibrosis AND placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    134 result(s) found for: Cystic Fibrosis AND placebo. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2016-001840-20 Sponsor Protocol Number: CTBM100C2412 Start Date*: 2016-05-18
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Usi...
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005080-33 Sponsor Protocol Number: FARM7K7XZB Start Date*: 2009-02-05
    Sponsor Name:AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
    Full Title: RANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONE VERSUS PLACEBO IN PATIENTS WITH CYSTIC FIBROSIS.
    Medical condition: Cystic fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009875-37 Sponsor Protocol Number: CF200901 Start Date*: 2009-03-11
    Sponsor Name:Staf Longziekten
    Full Title: A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes
    Medical condition: Cystic fibrosis-related diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012602 Diabetes mellitus (incl subtypes) HLT
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005085-37 Sponsor Protocol Number: CQBW251X2101 Start Date*: 2012-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy...
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) IE (Prematurely Ended) BE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004915-35 Sponsor Protocol Number: CQBW276X2201 Start Date*: 2017-07-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of inhaled QBW276 in patients with cystic fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002699-14 Sponsor Protocol Number: DPM-CF-204 Start Date*: 2013-01-28
    Sponsor Name:Pharmaxis Ltd.
    Full Title: A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to ...
    Medical condition: Cystic fibrosis in children aged 6 to 17 years
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004699-34 Sponsor Protocol Number: D4260C00008 Start Date*: 2008-10-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007416-15 Sponsor Protocol Number: VX08-770-102 Start Date*: 2009-08-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX 770 in Subjects with Cystic Fibrosis and the G551D Mutation
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002341-12 Sponsor Protocol Number: DEB-EPI-206 Start Date*: 2005-02-14
    Sponsor Name:Debiopharm SA
    Full Title: Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis Patients
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011762 PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002837-31 Sponsor Protocol Number: GLPG2222-CL-201 Start Date*: 2016-12-02
    Sponsor Name:Galapagos NV
    Full Title: A phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (cla...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-001156-43 Sponsor Protocol Number: 205.339 Start Date*: 2008-09-19
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respi...
    Medical condition: Cystic fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) NL (Completed) GB (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004837-13 Sponsor Protocol Number: VX14-661-106 Start Date*: 2015-06-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cy...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) GB (Completed) DK (Completed) IT (Completed) NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006446-25 Sponsor Protocol Number: VX08-809-101 Start Date*: 2009-08-26
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A randomized, double-blind, placebo-controlled, multiple dose study of VX-809 to evaluate safety, pharmacokinetics, and pharmacodynamics of VX-809 in cystic fibrosis subjects homozygous for the del...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    9.1 10011764 Cystic fibrosis NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003810-35 Sponsor Protocol Number: BMX-04-001 Start Date*: 2023-04-25
    Sponsor Name:BiomX Ltd.
    Full Title: A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomon...
    Medical condition: Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    22.1 100000004862 10082869 Chronic Pseudomonas aeruginosa infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001219-11 Sponsor Protocol Number: PNCRLPCYS3001 Start Date*: 2015-03-31
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
    Full Title: A randomized double-blind (withdrawal) phase 3 study to evaluate the efficacy and tolerability of pancrelipase MT capsules compared with placebo in the treatment of subjects with cystic fibrosis-d...
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10011765 Cystic fibrosis pancreas LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002677-38 Sponsor Protocol Number: CTX-4430-CF-201 Start Date*: 2016-02-04
    Sponsor Name:Celtaxsys Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002581-23 Sponsor Protocol Number: JBT101-CF-001 Start Date*: 2015-12-03
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis
    Medical condition: Cystic Fibrosis Cystic Fibrosis is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections, fibrosis of the lungs and digestive tract and abno...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000387-19 Sponsor Protocol Number: VX11-770-110 Start Date*: 2012-06-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis who Have the R117H-CFTR Mutation
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006693-24 Sponsor Protocol Number: Moli1901-010B Start Date*: 2007-05-09
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis
    Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) FR (Completed) DE (Completed) HU (Completed) SE (Completed) ES (Completed) PL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018454-13 Sponsor Protocol Number: SMB-NAL-III-09-1 Start Date*: 2010-08-31
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled N...
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:50:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA